Stella Diagnostics Selected as Buzz of BIO Winner for the 2020 BIO Investor Forum Digital
NEW YORK--(BUSINESS WIRE)-- Stella Diagnostics, Inc. (OTC Markets: JMDP), a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease, announced today that it was selected as the Buzz of BIO winner for the 2020 BIO Investor Forum Digital in the ‘Diagnostics and Beyond’ category. Stella Diagnostics also received an invitation to deliver a podium presentation about the company at the event to be held virtually on October 13-15, 2020.
The Buzz of BIO contest provides an excellent opportunity for companies to share their technology and commercial offerings. According to the BIO website, “…the BIO Investor Forum has become the premier event where biotech innovators can find strategic partners to advance their company to the next stage in their business life cycle.” The contest helps to identify U.S.-based companies with breakthrough, early stage technologies that have the potential to improve the lives of patients and yield an advantage in healthcare economics.
Joe Abdo, Co-founder and CEO of Stella Diagnostics said, “On behalf of the entire Stella team, we would like to thank BIO for nominating Stella as well as everyone who voted for Stella during the Buzz of BIO open voting competition. We are incredibly eager to demonstrate the paradigm shift that our diagnostic platform can bring to healthcare providers in the fields of gastroenterology, pathology and GI oncology.”
Scientific Advisor, Dr. Devendra Agrawal, noted that “Stella Diagnostics focuses on process innovation with the goal to deliver robust and actionable diagnostic data to providers treating millions of Americans living with severe esophageal disease. The technology was developed via rigorous research by domain experts and practicing physicians. We are looking forward to demonstrating to the BIO Investor Forum attendees how our discovery and algorithm can be incorporated into routine clinical sequences and concurrently yield critical diagnostic data in concert with standard of care screening protocols. This would allow the physicians and patients to make more informed decisions and achieve better outcomes.”
About Stella Diagnostics
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s mass spec proteomic assay will offer physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit (www.stelladx.com).
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
For more information visit: https://www.bio.org/
Follow us on Twitter @IAmBiotech
Find us on LinkedIn
STELLA DIAGNOSTICS CONTACTS:
Investors and Media Contact:
Joe Abdo, Chief Executive Officer
Stella Diagnostics, Inc.
Source: Stella Diagnostics, Inc.